CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy-Reference-Cited by-同舟云学术

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy

Published:2018-05-08 Issue:43 Volume:39 Page:3879-3892
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Mosqueira Diogo¹,Mannhardt Ingra²³,Bhagwan Jamie R¹,Lis-Slimak Katarzyna¹,Katili Puspita¹,Scott Elizabeth¹,Hassan Mustafa⁴,Prondzynski Maksymilian²³,Harmer Stephen C⁴,Tinker Andrew⁴,Smith James G W¹,Carrier Lucie²³,Williams Philip M⁵,Gaffney Daniel⁶,Eschenhagen Thomas²³,Hansen Arne²³,Denning Chris¹

Affiliation:

1. Department of Stem Cell Biology, Centre of Biomolecular Sciences, University of Nottingham, UK

2. Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

3. Partner Site Hamburg/Kiel/Lübeck, DZHK (German Center for Cardiovascular Research), Hamburg, Germany

4. The Heart Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London, UK

5. Molecular Therapeutics and Formulation. School of Pharmacy, University of Nottingham, UK

6. Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK

Funder

British Heart Foundation

Britain Israel Research and Academic Exchange Partnership

Medical Research Council

MICA

Development of Metrics and Quality Standards for Scale up of Human Pluripotent Stem Cells

National Centre for the Replacement, Refinement & Reduction of Animals in Research

German Research Foundation

European Research Council

European Commission

German Centre for Cardiovascular Research

DZHK

German Ministry of Education and Research

Freie und Hansestadt Hamburg

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/39/43/3879/26565407/ehy249.pdf

Reference86 articles.

1. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur Heart J,2014

2. New perspectives on the prevalence of hypertrophic cardiomyopathy;Semsarian;J Am Coll Cardiol,2015

3. Prevalence, Clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy;Harris;Circulation,2006

4. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals;Sedaghat-Hamedani;Clin Res Cardiol,2018

5. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy;Melacini;Eur Heart J,2010

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modelling neurocardiac physiology and diseases using human pluripotent stem cells: current progress and future prospects;The Journal of Physiology;2024-09-05

2. Computer Vision for Substrate Detection in High‐Throughput Biomaterial Screens Using Bright‐Field Microscopy;Advanced Intelligent Systems;2024-08-22

3. Studying Pathogenetic Contribution of a Variant of Unknown Significance, p.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells;International Journal of Molecular Sciences;2024-08-09

4. Human heart-on-a-chip microphysiological system comprising endothelial cells, fibroblasts, and iPSC-derived cardiomyocytes;Scientific Reports;2024-08-08

5. Mitochondrial dysfunction in the pathogenesis of hypertrophic cardiomyopathy;Morphology;2024-07-30